195 Recruiting Trials

Clinical Trials
for Cancer in Arkansas

195 clinical trials for Cancer are currently recruiting participants at study sites in Arkansas. Study-related care is provided at no cost.

195
Recruiting trials
73
Study sites
13
Cities
103
Industry-sponsored
59
Phase 2
105
Phase 3

Cancer clinical trials in Arkansas: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Arkansas, recruiting cancer studies are concentrated in Little Rock, Springdale, Jonesboro and Fort Smith, with sites in 9 other cities. 103 of the 195 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 195 recruiting Cancer trials in Arkansas

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
PHASE2 Little Rock, Arkansas +4 sites NCT05997017
This trial is looking for women with advanced or recurrent endometrioid endometrial cancer to test a combination of two medications. Participants must have measurable disease and meet certain health criteria to join the study.
Recruiting
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
NA Jonesboro, Arkansas +4 sites NCT06756607
This trial is looking for Black and Latino cancer patients who want to improve awareness and access to clinical trials. Participants will engage with resources and support to help connect them with research opportunities.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
PHASE3 Little Rock, Arkansas +4 sites NCT06510374
This trial is looking for people with intermediate risk non-muscle invasive bladder cancer. Participants will either receive a treatment called Nadofaragene Firadenovec or be monitored without treatment.
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
PHASE3 Little Rock, Arkansas +4 sites NCT06545955
This trial is looking for adults with a specific type of bladder cancer called carcinoma in situ (CIS) who have not responded to previous treatments. Participants will receive a treatment called nadofaragene firadenovec, either alone or with other therapies, to see how well it works.
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
PHASE3 Springdale, Arkansas +4 sites NCT07625644
This trial is looking for adults with extensive-stage small cell lung cancer who have not received treatment before. Participants will receive a combination of two medications, BL-M14D1 and Atezolizumab, to see how well it works compared to standard therapy.
Recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
PHASE3 Hot Springs, Arkansas +4 sites NCT07775287
This trial is looking for people with colorectal cancer that has come back or spread and cannot be removed by surgery. Participants will take either petosemtamab with chemotherapy or standard treatment options with chemotherapy, with regular visits for testing.
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
PHASE3 Little Rock, Arkansas +4 sites NCT06079671
This trial is looking for women with high-risk locally advanced cervical cancer who have not progressed after treatment. Participants will receive volrustomig to see how well it works and what side effects it may cause.
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
PHASE3 Hot Springs, Arkansas +4 sites NCT06646276
This trial is looking for people with extensive-stage small cell lung cancer. Participants will receive one of two different treatment combinations and will be monitored for their health and tumor response.
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
PHASE3 Little Rock, Arkansas +4 sites NCT07472517
This trial is looking for adults with advanced small cell lung cancer. Participants will receive either a study medicine called obrixtamig along with standard treatment or just the standard treatment alone. The goal is to see if the study medicine helps improve survival.
Recruiting
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
PHASE3 Anchorage, Alaska +4 sites NCT07018869
This trial is looking for people who have recently been diagnosed with stage II or III colorectal cancer and want to improve their follow-up care. Participants will use an educational website with a supportive person in their life to learn about managing their health after cancer treatment.
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3 Fort Smith, Arkansas +4 sites NCT06748222
This trial is looking for younger women who have survived breast cancer and are experiencing depression. Participants will try two different mindfulness programs, one led by an instructor via Zoom and the other through a mobile app.
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
PHASE3 Fort Smith, Arkansas +4 sites NCT07409272
This trial is looking for people with pancreatic cancer that has spread and a specific gene mutation. Participants will receive a medication called setidegrasib along with standard chemotherapy to see if it helps improve their treatment outcomes.
Recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
PHASE3 Hot Springs, Arkansas +4 sites NCT07702032
This trial is looking for people with left-sided colorectal cancer that cannot be removed with surgery. Participants will receive treatment with either petosemtamab plus chemotherapy or standard care cetuximab plus chemotherapy while undergoing regular check-ups.
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
PHASE3 Little Rock, Arkansas +4 sites NCT06072781
This trial is looking for patients with recurring low-grade serous ovarian cancer. Participants will receive a combination of two drugs to see how they work together after previous treatments.
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
PHASE2 Goodyear, Arizona +4 sites NCT04613596
This trial is looking for patients with advanced non-small cell lung cancer who have a specific mutation. Participants will receive treatments to see how well they work.
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
PHASE3 Chandler, Arizona +4 sites NCT06629779
This trial is looking for men with advanced prostate cancer. Participants will receive a new drug along with enzalutamide to see if this combination works better than enzalutamide alone.
Recruiting

Where the Cancer studies are in Arkansas

  • University of Arkansas for Medical Sciences, Little Rock45 trials
  • Highlands Oncology Group, Springdale35 trials
  • Mercy Hospital Fort Smith, Fort Smith32 trials
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro31 trials
  • CARTI Cancer Center, Little Rock21 trials
  • Highlands Oncology Group - Fayetteville, Fayetteville14 trials

Counts are recruiting studies listing at least one site in Arkansas, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Arkansas: common questions

How many Cancer clinical trials are recruiting in Arkansas?
TrialFinder currently lists 195 recruiting Cancer clinical trials with study sites in Arkansas. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Arkansas?
Study sites for the Cancer trials listed on this page include Little Rock, Jonesboro, Springdale, Hot Springs, Fort Smith. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Arkansas?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Arkansas also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Arkansas?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Arkansas.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →